STE — STERIS plc

STERIS plc Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Grew 9% year-over-year; constant currency organic revenue increased by 8%.
• Gross Margin: Declined by 70 basis points to 43.9%, affected by increased tariffs and inflation.
• EBIT Margin: Decreased by 40 basis points to 22.9%, primarily due to the decline in gross margin.
• Adjusted Net Income: $249.4 million; earnings per diluted share increased by 9% to $2.53.
• Free Cash Flow: $7.368 billion for the first nine months of fiscal 2026, with year-over-year improvement.
• Debt: Total debt stood at $1.9 billion, with a gross debt to EBITDA ratio of approximately 1.2.

2. Strategic Updates and Business Highlights

• Healthcare Segment: Constant currency organic revenue grew 8%, with service revenue up 11%. Capital equipment revenue increased by 7%, and backlog remains over $400 million.
• AST Segment: Constant currency organic revenue also grew 8%, driven by a 103% increase in capital equipment revenue. EBIT margins improved to 45.1%.
• Life Sciences: Revenue increased by 5%, with 11% growth in consumables. Backlog holds over $100 million.
• Tariff Mitigation Efforts: The company is implementing various strategies to offset tariff impacts, including supplier negotiations and operational efficiencies.

3. Forward Guidance and Outlook

• Fiscal 2026 Guidance: Maintaining revenue growth outlook of 8% to 9% as-reported and 7% to 8% constant currency organic revenue growth. Earnings per share guidance remains at $10 to $10.30.
• Free Cash Flow: Expected to be $850 million, with capital expenditures unchanged at $375 million.

4. Bad News, Challenges, or Points of Concern

• Margin Pressures: Gross and EBIT margins are under pressure due to tariffs and inflation, with a noted $10 million increase in anticipated tariff costs.
• Order Trends: Year-to-date orders in healthcare are down 1%, indicating potential challenges in sustaining growth against tough comparisons from the previous year.
• Market Comparisons: The fourth quarter is expected to face a tough comparison to last year, particularly in the AST segment, which had a strong capital equipment performance.

5. Notable Q&A Insights

• Fourth Quarter Expectations: Management cautioned against expecting significant growth in Q4, citing a slowdown in the second half of the fiscal year.
• Capital Equipment Backlog: Life sciences backlog is recovering, while healthcare backlog remains stable, with no significant slowdown in capital spending noted.
• Regulatory Changes: Discussions on potential impacts from CMS proposals regarding onshoring and surgical procedure shifts were addressed, with a generally positive outlook for STERIS.
• Acquisition Strategy: The company has been focused on smaller acquisitions and remains disciplined in pursuing larger deals, indicating a cautious but active M&A strategy.
• Tariff Impact: Ongoing tariff costs are being absorbed through various mitigation strategies, but the impact on future earnings remains a concern.

This summary encapsulates STERIS plc's Q3 2026 performance, highlighting financial results, strategic initiatives, guidance, and challenges faced in the current market environment.